Meta-analysis of 5 RCTs (1,699 postmenopausal women): elinzanetant reduced hot flush frequency (MD -2.75 at week 4; -2.30 at week 12) and severity vs placebo, but raised adverse events, discontinuations, headache, somnolence and fatigue; serious events did not differ.
Meta-analysisn = 1,699
Afifi et al. Elinzanetant: Efficacy and safety in the management of vasomotor symptoms in postmenopausal women, a systematic review and meta-analysis with grading of recommendations assessment, development, and evaluation assessment